07:46 AM EDT, 06/18/2025 (MT Newswires) -- Senti Biosciences ( SNTI ) said Wednesday that the US Food and Drug Administration has granted orphan drug designation for SENTI-202, a drug candidate for relapsed or refractory acute myeloid leukemia.

The experimental drug is a first, off-the-shelf cancer immunotherapy natural killer cell treatment designed to target acute myeloid leukemia and other hematologic malignancies, the company said.

Senti-202 is currently being evaluated in a phase 1 clinical trial to assess its safety and efficacy, Senti Biosciences ( SNTI ) said.

The orphan drug designation provides benefits such as tax credits, exemptions from certain FDA fees, and potential market exclusivity for seven years, the company added.